Abstract
Efforts to improve the potency and pharmacokinetic properties of small molecule factor VIIa inhibitors are described. Small structural modifications to existing leads allow the modulation of half-life and clearance, potentially making these compounds suitable candidates for drug development.
MeSH terms
-
Animals
-
Anticoagulants / pharmacokinetics*
-
Blood Coagulation / drug effects*
-
Drug Design
-
Factor VIIa / antagonists & inhibitors*
-
Half-Life
-
Humans
-
Molecular Structure
-
Serine Proteinase Inhibitors / pharmacokinetics*
-
Structure-Activity Relationship
Substances
-
Anticoagulants
-
Serine Proteinase Inhibitors
-
Factor VIIa